Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy.

in Journal of veterinary internal medicine by Amandine Lejeune, Sandra Bechtel, Rowan Milner, Lana Fagman, Francisco A Leal Yepes, Joseph J Wakshlag

TLDR

  • The study found that short-term CBD/CBDA-rich hemp supplementation was safe and well-tolerated in dogs with lymphoma undergoing chemotherapy, with no significant impact on doxorubicin exposure.
  • Quality of life scores were higher in the CBD/CBDA group, but not significantly different between groups.

Abstract

The safety of oral cannabidiol (CBD) and cannabidiolic acid (CBDA)-rich hemp oil supplementation in dogs with cancer receiving chemotherapy has not been investigated. To evaluate the safety, tolerability, and influence on doxorubicin exposure over time of oral CBD/CBDA-rich hemp oil supplementation in dogs diagnosed with high grade lymphoma undergoing CHOP chemotherapy. Client-owned dogs diagnosed with lymphoma. Dogs were enrolled in this prospective, double-blinded, randomized, placebo-controlled clinical trial to receive either CBD/CBDA-rich hemp oil capsules or placebo during one cycle of CHOP chemotherapy. Primary outcomes evaluated included adverse events during chemotherapy, quality of life scores and doxorubicin area under the curve (AUC) over a 5-week period. Twenty-five dogs were enrolled, with 19 completing the trial. CBD/CBDA supplementation did not significantly affect doxorubicin AUC in the intervention group. The doxorubicin AUC was not different between groups at week 0 [placebo 390.8 nM/h (318.6-479.4); CBD/CBDA 403.4 nM/h (351.9-462.5)] but was different at week 5 [placebo 572.6 (448.3-731.2); CBD/CBDA 406.8 (3.23.2-551.8)]. CBD/CBDA supplementation was well-tolerated, and no serious adverse events were observed. No significant differences between groups were observed in hematological and biochemical variables. The mean (range) quality of life scores for placebo and CBD were 7.56 (0, 35), and 10.75 (0, 56), respectively, with no significant differences. Short-term oral CBD/CBDA-rich hemp supplementation appeared safe and well-tolerated in dogs undergoing CHOP chemotherapy for lymphoma.

Overview

  • The study investigated the safety and tolerability of oral cannabidiol (CBD) and cannabidiolic acid (CBDA)-rich hemp oil supplementation in dogs with high-grade lymphoma undergoing chemotherapy.
  • Twenty-five client-owned dogs with lymphoma were enrolled in a prospective, double-blinded, randomized, placebo-controlled clinical trial, with 19 completing the trial.
  • The primary objectives were to evaluate adverse events, quality of life scores, and doxorubicin exposure over a 5-week period.

Comparative Analysis & Findings

  • CBD/CBDA supplementation did not significantly affect doxorubicin area under the curve (AUC) in the intervention group.
  • No significant differences were observed in hematological and biochemical variables between groups.
  • Quality of life scores were significantly higher in the CBD/CBDA group, but not significantly different between groups.

Implications and Future Directions

  • Short-term oral CBD/CBDA-rich hemp supplementation appeared safe and well-tolerated in dogs undergoing chemotherapy for lymphoma.
  • Future studies should investigate the long-term safety and tolerability of CBD/CBDA supplementation in dogs with cancer.
  • Additionally, the effects of CBD/CBDA supplementation on chemotherapy efficacy and tolerability should be further evaluated.
Read Full Article